文献速递产科母胎医学

伐昔洛韦在预防母胎巨细胞病毒传播中的新疗效数据

New data on efficacy of valacyclovir in secondary prevention of maternal-fetal transmission of cytomegalovirus.
PubMed 文献 · Ultrasound Obstet Gynecol · 2023-01-01

这项回顾性多中心研究评估了伐昔洛韦(VCV)每日8g治疗对母体原发巨细胞病毒(CMV)感染后母胎传播的预防效果。倾向性评分校正后,VCV治疗与母胎CMV传播率总体降低显著相关(OR 0.40,95%CI 0.18-0.90;P=0.029)。作者认为VCV可降低母胎CMV传播风险,且对第一和第二孕期原发感染可能有效。

要点

  • 倾向性评分校正后,VCV治疗与母胎CMV传播率显著降低相关(OR 0.40;95%CI 0.18-0.90;P=0.029)。
  • 第一孕期原发感染后传播率VCV组22%(8/36)vs 对照组41%(19/46),P=0.068。
  • 第二孕期原发感染后传播率VCV组25%(2/8)vs 对照组52%(14/27),P=0.244。

核心结论

  • VCV治疗孕妇原发CMV感染可降低母胎CMV传播风险,且对第一和第二孕期原发感染可能有效。

研究设计与样本

  • 回顾性多中心研究,比较接受VCV每日8g治疗的孕妇与未治疗对照组,最终分析纳入143例(VCV组59例,对照组84例),所有病例均经病毒学检测确认母体原发感染并确定感染起始时间。
  • 主要结局为出生时经唾液、尿液和/或血液样本聚合酶链反应分析诊断的先天性CMV感染。
  • 采用倾向性评分校正的逻辑回归分析评估VCV疗效。

主要发现

  • 倾向性评分校正分析显示,VCV治疗与母胎CMV传播率总体降低显著相关(OR 0.40;95%CI 0.18-0.90;P=0.029)。
  • 围受孕期母体原发感染后出生时母胎CMV传播率:VCV组7%(1/14)vs 对照组10%(1/10),P=1.00。
  • 第一孕期母体原发感染后传播率:VCV组22%(8/36)vs 对照组41%(19/46),P=0.068。
  • 第二孕期母体原发感染后传播率:VCV组25%(2/8)vs 对照组52%(14/27),P=0.244。
  • 按治疗开始时母体病毒血症分析:病毒血症阳性者传播率VCV组21% vs 对照组43%(P=0.072),病毒血症阴性者VCV组22% vs 对照组17%(P=0.659),病毒血症阳性者呈现疗效更佳的趋势。

关键数值与推荐

  • VCV剂量为每日8g。
  • 先天性CMV感染诊断基于唾液、尿液和/或血液样本的聚合酶链反应分析。
  • 疗效评估采用倾向性评分校正的逻辑回归分析。

临床怎么用

  • 作者认为,对原发CMV感染的孕妇给予VCV治疗可降低母胎CMV传播风险,且对第一和第二孕期原发感染可能有效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Congenital cytomegalovirus (CMV) infection is the leading cause of non-genetic hearing and neurological deficits. The aim of our study was to evaluate the efficacy and safety of valacyclovir (VCV) treatment in preventing CMV transmission to the fetus after maternal primary infection. METHODS: This was a retrospective, multicenter study evaluating the rate of maternal-fetal CMV transmission in pregnancies with maternal primary CMV infection treated with VCV at a dosage of 8 g per day (VCV group) compared with a control group of untreated women. Each case underwent virological testing to confirm maternal primary infection and to provide accurate dating of onset of infection. The primary outcome was the presence of congenital CMV infection at birth diagnosed based on polymerase chain reaction analysis of saliva, urine and/or blood samples. The efficacy of VCV treatment was assessed using logistic regression analysis adjusted for a propensity score. RESULTS: In total, 143 patients were included in the final analysis, of whom 59 were in the VCV group and 84 were in the untreated control group. On propensity-score-adjusted analysis, VCV treatment was significantly associated with an overall reduction in the rate of maternal-fetal CMV transmission (odds ratio, 0.40 (95% CI, 0.18-0.90); P = 0.029). The rate of maternal-fetal CMV transmission, determined at birth, in the VCV vs control group was 7% (1/14) vs 10% (1/10) after periconceptional maternal primary infection (P = 1.00), 22% (8/36) vs 41% (19/46) after first-trimester maternal primary infection (P = 0.068) and 25% (2/8) vs 52% (14/27) after second-trimester maternal primary infection (P = 0.244). When analyzing the efficacy of VCV treatment according to maternal viremia at treatment initiation, there was a trend towards greater efficacy when patients were viremia-positive (21% vs 43%; P = 0.072) compared with when they were viremia-negative (22% vs 17%; P = 0.659). Maternal side effects associated with VCV were mild and non-specific in most cases. CONCLUSION: Our findings indicate that VCV treatment of pregnant women with primary CMV infection reduces the risk of maternal-fetal transmission of CMV and may be effective in cases with primary infection in the first and second trimesters. © 2022 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Egloff C, Sibiude J, Vauloup-Fellous C, et al. New data on efficacy of valacyclovir in secondary prevention of maternal-fetal transmission of cytomegalovirus. Ultrasound Obstet Gynecol. 2023. PMID: 35900718. doi:10.1002/uog.26039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。